Personal information

Activities

Collapse all

Works (9)

Insights into the future of first-line advanced hepatocellular carcinoma treatment.

The Lancet. Oncology
2025-01-21 | Journal article
DOI: 10.1016/s1470-2045(24)00728-9
PMID: 39855250
Contributors: Wong JSL; Wong CC; Sun FSK; Yau T
Source: Self-asserted source
Jeffrey Wong

Evolution of systemic therapy for advanced HCC patients: Did we make progress in 2022?

Hepatology Communications
2023-06 | Journal article
DOI: 10.1097/HC9.0000000000000117
Contributors: Jeffrey Sum Lung Wong; Roland Leung; Tan To Cheung; Thomas Yau
Source: check_circle
Crossref

Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.

Oncoimmunology
2023-06-03 | Journal article
DOI: 10.1080/2162402x.2023.2214478
PMID: 37284696
PMC: PMC10241000
Contributors: Benjamin Koh; Tan DJH; Lim WH; Wong JSL; Ng CH; Chan KE; Wang M; Yong WP; Dan YY; Wang LZ et al.
Source: Self-asserted source
Jeffrey Wong

Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma.

Journal of the National Cancer Institute
2022-09-01 | Journal article
DOI: 10.1093/jnci/djac051
PMID: 35288743
PMC: PMC9468280
Contributors: Kikuchi H; Matsui A; Satoru Morita; Amoozgar Z; Inoue K; Ruan Z; Staiculescu D; Wong JS; Huang P; Yau T et al.
Source: Self-asserted source
Jeffrey Wong

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.

Journal of Clinical Oncology
2021 | Journal article
DOI: 10.1200/JCO.2021.39.3\_suppl.330
Source: Self-asserted source
Jeffrey Wong

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC

Cancers
2021 | Journal article
DOI: 10.3390/cancers13081949
Part of ISSN: 2072-6694
Source: Self-asserted source
Jeffrey Wong

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study

Cancers
2021 | Journal article
DOI: 10.3390/cancers13092002
Part of ISSN: 2072-6694
Source: Self-asserted source
Jeffrey Wong

Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.

Expert review of gastroenterology & hepatology
2021-03-05 | Journal article
DOI: 10.1080/17474124.2021.1899808
PMID: 33666530
Source: Self-asserted source
Jeffrey Wong

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

Journal for ImmunoTherapy of Cancer
2021-02 | Journal article
DOI: 10.1136/jitc-2020-001945
Contributors: Jeffrey Sum Lung Wong; Gerry Gin Wai Kwok; Vikki Tang; Bryan Cho Wing Li; Roland Leung; Joanne Chiu; Ka Wing Ma; Wong Hoi She; Josephine Tsang; Chung Mau Lo et al.
Source: check_circle
Crossref

Peer review (1 review for 1 publication/grant)

Review activity for Journal for immunotherapy of cancer. (1)
How many people are using ORCID?